275 filings
Page 4 of 14
8-K
ixhwam
2 May 23
Preliminary results demonstrate a durable complete response at starting dose level in elderly subject
8:35am
8-K
1jc0ihlr 2uvta
18 Apr 23
Sponsored research data presented in a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2023
1:35pm
8-K
ju2czjdc5itb9dz a6
3 Apr 23
Regulation FD Disclosure
7:00am
8-K
frlux
23 Mar 23
Moleculin Reports Full Year 2022 Financial Results and Provides Pipeline Update
8:20am
8-K
6un5bi0um2yywfbk1
22 Mar 23
Regulation FD Disclosure
4:20pm
8-K
zc5ufeanf7b 4ke3vub7
15 Mar 23
Regulation FD Disclosure
8:30am
8-K
pblvd
13 Mar 23
Moleculin Announces it Has No Exposure to Silicon Valley Bank Situation
7:05am
8-K
0ny2y9 pi
9 Mar 23
Regulation FD Disclosure
8:35am
8-K
xcrsa2th
1 Mar 23
Regulation FD Disclosure
8:45am
8-K
07t3s9
13 Feb 23
Regulation FD Disclosure
8:11am
8-K
q2f5ey q9e9
8 Feb 23
Regulation FD Disclosure
5:00pm
8-K
73vbxnsue93juh
3 Feb 23
Termination of a Material Definitive Agreement
5:20pm
8-K
qwfh0z8qj6m wscq7j7
21 Dec 22
Regulation FD Disclosure
8:25am
8-K
ljajh186anqsa4r3
15 Dec 22
Preliminary efficacy updated to 80% overall response rate (ORR) demonstrated in single agent AML trial following database lock
8:37am
8-K
8v55tb00u 2h
7 Dec 22
Moleculin Granted FDA Fast Track Designation of WP1122 for the Treatment of Glioblastoma Multiforme
8:45am
8-K
kta9q3 f80bry2c0n
14 Nov 22
Regulation FD Disclosure
8:00am
8-K
x8yeub 3q
10 Nov 22
Moleculin Reports Third Quarter 2022 Financial Results and Provides Pipeline Update
4:11pm
8-K
asgzbamb8c e5m
14 Oct 22
Moleculin Provides Update on Second Multiple Ascending Dose (MAD) Cohort in Phase 1a Clinical Trial of WP1122 in the UK
8:40am
8-K
nc56ud
27 Sep 22
Regulation FD Disclosure
8:36am
8-K
x18w 8nsv
9 Sep 22
Regulation FD Disclosure
4:00pm